Suppr超能文献

1998-2008 年土耳其一家儿科移植中心的造血干细胞移植活动和趋势。

Hematopoietic stem cell transplantation activity and trends at a pediatric transplantation center in Turkey during 1998-2008.

机构信息

Akdeniz University, School of Medicine, Department of Pediatric Hematology, Oncology and BMT Unit, Antalya, Turkey.

出版信息

Turk J Haematol. 2012 Jun;29(2):143-9. doi: 10.5505/tjh.2012.78300. Epub 2012 Jun 15.

Abstract

OBJECTIVE

The aim of this study was to document hematopoietic stem cell transplantation (HSCT) activity and trends at our treatment center.

MATERIAL AND METHODS

Data collected over a 10-year period were retrospectively analyzed, concentrating primarily on types of HSCT, transplant-related mortality (TRM), stem cell sources, indications for HSCT, and causes of death following HSCT.

RESULTS

In total, 222 allogeneic (allo)-HSCT (87.4%) and 32 autologous (auto)-HSCT (12.6%) procedures were performed between 1998 and 2008. Stem cells obtained from unrelated donors were used in 22.6% (50/222) of the allo- HSCTs. Cord blood was the source of hematopoietic stem cells (HSC) in 12.2% of all transplants. The most common indication for allo-HSCT was hemoglobinopathy (43.2%), versus neuroblastoma (53.1%) for auto-HSCT. The TRM rate 1 year post transplantation was 18.3% ± 2.5% for all transplants, but differed according to transplantation type (23.5% ± 7.9% for auto-HSCT and 17.5% ± 2.6% for allo-HSCT). The most common cause of death 1 year post HSCT was infection (35.9%).

CONCLUSION

The TRM rate in the patients that underwent allo-HSCT was similar to that which has been previously reported; however, the TRM rate in the patients that underwent auto-HSCT was higher than previously reported in developed countries. The selection of these patients to be transplanted must be made attentively.

摘要

目的

本研究旨在记录我们治疗中心的造血干细胞移植(HSCT)活动和趋势。

材料和方法

对 10 年来收集的数据进行回顾性分析,主要集中在 HSCT 的类型、移植相关死亡率(TRM)、干细胞来源、HSCT 的适应证以及 HSCT 后死亡的原因。

结果

在 1998 年至 2008 年间,共进行了 222 例异基因(allo)-HSCT(87.4%)和 32 例自体(auto)-HSCT(12.6%)。在 22.6%(50/222)的 allo-HSCT 中使用了来自无关供者的干细胞。在所有移植中,脐带血是造血干细胞(HSC)的来源,占 12.2%。allo-HSCT 的最常见适应证是血红蛋白病(43.2%),而自体 HSCT 的最常见适应证是神经母细胞瘤(53.1%)。移植后 1 年的 TRM 率为所有移植的 18.3%±2.5%,但根据移植类型而有所不同(自体 HSCT 为 23.5%±7.9%,allo-HSCT 为 17.5%±2.6%)。移植后 1 年最常见的死亡原因是感染(35.9%)。

结论

allo-HSCT 患者的 TRM 率与以往报道相似,但自体 HSCT 患者的 TRM 率高于以往报道的发达国家。对这些患者进行移植的选择必须慎重。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验